Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 13/20 | 0.73 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12069335 | 0.85 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL12069325 | 0.84 | SLC22A12 (0.68) | SLC22A12ABL1 | |
| SCHEMBL12070370 | 0.84 | SLC22A12 (0.62) | SLC22A12 | |
| SCHEMBL12070741 | 0.84 | SLC22A12 (0.63) | SLC22A12SRCRIPK2 | |
| SCHEMBL12069337 | 0.81 | SLC22A12 (0.67) | SLC22A12RIPK2 | |
| SCHEMBL12069346 | 0.78 | SLC22A12 (0.81) | SLC22A12 | |
| SCHEMBL12069344 | 0.77 | SLC22A12 (0.65) | SLC22A12 | |
| SCHEMBL12070853 | 0.77 | SLC22A12 (0.63) | SLC22A12 | |
| SCHEMBL12070871 | 0.77 | SLC22A12 (0.66) | SLC22A12 | |
| SCHEMBL12069336 | 0.76 | SLC22A12 (0.77) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171466-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AREDEA BIOSCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10919858-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3611167-A1 | THIOACETATE COMPOUND AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190185431-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10266493-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2975025-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2712861-B1 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2585437-B1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8629278-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629278-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130281469-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281469-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8541589-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541589-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2011159839-A2 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
| US-10266493-B2 | Thioacetate compounds, compositions and methods of use | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
| US-20210171466-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
| US-10919858-B2 | Thioacetate compounds, compositions and methods of use | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
| US-20130281469-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
| US-20190185431-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SRC 3819/4885RIPK2 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.